Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
NRAS wild-type
i
Other names:
NRAS1, N-Ras Protein Part 4, Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, NRAS, Neuroblastoma RAS Viral Oncogene Homolog, NRAS Proto-Oncogene, GTPase
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4893
Related biomarkers:
Expression
Mutation
CNA
Others
‹
NRAS amplification (4)
NRAS amplification (4)
›
Related tests:
FoundationOne® CDx (110)
MI Cancer Seek™
FoundationOne® CDx (110)
MI Cancer Seek™
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
NRAS wild-type
Rectal Cancer
NRAS wild-type
Rectal Cancer
panitumumab
Sensitive: A2 - Guideline
panitumumab
Sensitive
:
A2
panitumumab
Sensitive: A2 - Guideline
panitumumab
Sensitive
:
A2
NRAS wild-type
Colon Cancer
NRAS wild-type
Colon Cancer
panitumumab
Sensitive: A2 - Guideline
panitumumab
Sensitive
:
A2
panitumumab
Sensitive: A2 - Guideline
panitumumab
Sensitive
:
A2
NRAS wild-type
Colon Cancer
NRAS wild-type
Colon Cancer
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
NRAS wild-type
Rectal Cancer
NRAS wild-type
Rectal Cancer
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
NRAS wild-type
Colorectal Cancer
NRAS wild-type
Colorectal Cancer
panitumumab
Sensitive: C2 – Inclusion Criteria
panitumumab
Sensitive
:
C2
panitumumab
Sensitive: C2 – Inclusion Criteria
panitumumab
Sensitive
:
C2
NRAS wild-type
Colorectal Cancer
NRAS wild-type
Colorectal Cancer
CPGJ-602
Sensitive: C2 – Inclusion Criteria
CPGJ-602
Sensitive
:
C2
CPGJ-602
Sensitive: C2 – Inclusion Criteria
CPGJ-602
Sensitive
:
C2
NRAS wild-type
Colorectal Cancer
NRAS wild-type
Colorectal Cancer
cetuximab
Resistant: C3 – Early Trials
cetuximab
Resistant
:
C3
cetuximab
Resistant: C3 – Early Trials
cetuximab
Resistant
:
C3
NRAS wild-type
Colorectal Cancer
NRAS wild-type
Colorectal Cancer
SCT200
Sensitive: C3 – Early Trials
SCT200
Sensitive
:
C3
SCT200
Sensitive: C3 – Early Trials
SCT200
Sensitive
:
C3
NRAS wild-type
Melanoma
NRAS wild-type
Melanoma
PD1 inhibitor
Sensitive: C3 – Early Trials
PD1 inhibitor
Sensitive
:
C3
PD1 inhibitor
Sensitive: C3 – Early Trials
PD1 inhibitor
Sensitive
:
C3
NRAS wild-type
Glioblastoma
NRAS wild-type
Glioblastoma
panitumumab
Sensitive: C3 – Early Trials
panitumumab
Sensitive
:
C3
panitumumab
Sensitive: C3 – Early Trials
panitumumab
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login